<DOC>
	<DOCNO>NCT01604863</DOCNO>
	<brief_summary>The primary purpose study determine maximally tolerate dose ( MTD ) HGS1036 use combination standard chemotherapeutic regimen paclitaxel plus carboplatin , cisplatin plus etoposide , docetaxel .</brief_summary>
	<brief_title>A Study HGS1036 Combination With Chemotherapy Subjects With Advanced Solid Malignancies</brief_title>
	<detailed_description>This study consist 3 regimen contain 2 dose level HGS1036 full dose chemotherapy . Patients treat sequence HGS1036 plan dose level 10 mg/kg 20 mg/kg . Patients demonstrate stable disease well may continue receive HGS1036 progressive disease , unacceptable toxicity , patient request discontinuation study treatment , Investigator feel treatment patient 's best interest . After discontinuation HGS1036 , subject follow 30 day last dose HGS1036 safety . The end study define 1 year last subject begin treatment HGS1036 . Any subject still receive HGS1036 pre-defined end study , may continue receive HGS1036 , study assessment require safety .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Have histological cytological diagnosis malignant solid neoplasm require systemic chemotherapy . Age ≥18 year . ECOG performance status 01 . Adequate organ function . Adequate hematological function . Have ability understand requirement study , provide write informed consent , comply study protocol procedure . Consent collection previously obtain , archival biopsy surgical specimen currently treat malignancy available . Significant cardiac disease . Eye trauma disease . Ocular surgery blunt force trauma eye require treatment within 3 month prior first dose HGS1036 . Presence history ≥ Grade 2 hemoptysis within 2 week first dose HGS1036 . Major surgery within 4 week first dose HGS1036 . Prior organ allogeneic stem cell transplant . Nonhealing chronic wound . Receipt anticancer therapy within 4 week prior first dose HGS1036 . Receipt biological therapy ( monoclonal antibody ) within 6 week first dose HGS1036 . Active CNS involvement primary metastatic tumor . Documented active infection require use systemic antibiotic . Pregnancy lactation . Known HIVpositive serology , AIDS , AIDSrelated illness . Conditions likely increase potential abdominal perforation fistula formation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Mesothelioma</keyword>
	<keyword>Small Cell lung Cancer</keyword>
</DOC>